News | October 17, 2023
Lupin enters into BTA with Lupin Manufacturing Solutions
Lupin enters into BTA with Lupin Manufacturing Solutions
Lupin enters into BTA with Lupin Manufacturing Solutions
Lupin is exclusive first-to-file and may be eligible to receive a 180-day exclusivity period at product launch
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
The company had submitted a comprehensive Corrective and Preventive Action (CAPA) plan in September 2022
Sugammadex Injection is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide
Tolvaptan Tablets (RLD Jynarque) had estimated annual sales of USD 287 million in the U.S. (IQVIA MAT August 2023)
Balaxi Healthcare Ecuador S.A.S. has become a Wholly Owned Subsidiary of the company
The U.S. FDA has determined that the inspection classification of the facility is Voluntary Action Indicated
The delegation's visit covered a wide range of topics
Mankind Pharma commences the commercial operations newly set-up plant in Udaipur
Subscribe To Our Newsletter & Stay Updated
